The ef®cacy and safety of sildena®l were evaluated in a randomised, double-blind, placebocontrolled,¯exible-dose study in Taiwanese men aged 26 to 80 y with erectile dysfunction (ED) of broad-spectrum aetiology and more than 6 months' duration. A total of 236 patients were randomised at six medical centres in Taiwan to receive either sildena®l (50 mg initially increased if necessary to 100 mg or decreased to 25 mg depending on ef®cacy and toleration) (n 119) or matching placebo (n 117) taken on an`as needed' basis 1 h prior to anticipated sexual activity for a period of 12 weeks. At the end of 12 weeks, the primary ef®cacy variables relating to the achievement and maintenance of erections suf®cient for sexual intercourse, and the secondary ef®cacy variables, which included: (1) the ®ve separate domains of sexual functioning of the IIEF (International Index of Erectile Function) scale, (2) the percentage of successful intercourse attempts; and (3) a global assessment of erections, were all statistically signi®cantly improved by sildena®l in comparison with placebo (P`0.0001). Treatment-related adverse events occurred in 43.7% of patients receiving sildena®l and 18.8% receiving placebo. The most common adverse events with sildena®l were¯ushing, dizziness and headache (25.2, 6.7 and 5.9% of patients, respectively), and most were mild in nature. The ef®cacy and safety of sildena®l in the population of Taiwanese men appears similar to that reported in other studies in western populations.
Introduction
Erectile dysfunction (ED) is de®ned as the inability to attain andaor maintain penile erection suf®cient to permit satisfactory sexual performance. 1 Although not a life-threatening disorder, ED profoundly in¯uences the social interactions, selfesteem and quality of life of individuals who suffer from it. In Taiwan, as in other populations, its exact prevalence is unknown, as cultural, religious and socioeconomic factors in¯uence the willingness of sufferers to seek medical advice and give rise to prevalence variations across geographical groups. However, if the prevalence of ED is comparable to the US, where the combined prevalence of minimal, moderate and complete ED was as high as 52% in one study of men aged 40 ± 70 y, 2 the magnitude of the problem in Taiwan is likely to be very great. Epidemiological studies from other Asian countries support this conclusion; for example, a study of men living in urban areas of Shanghai estimated that the incidence of ED was 32.8% at age 40 ± 49 y, increasing to 36.4% at 50 ± 59 y, 74.2% at 60 ± 69 y, and 86.3% in those over 70 y. 3 In addition to aging, many factors contribute to the development of ED, which include a variety of physical and psychological disorders such as diabetes mellitus, cardiovascular disease, renal and hepatic failure, neurological disease, certain drugs (eg some antihypertensives and antidepressants), certain types of surgery (eg pelvic or transurethral surgery), pelvic trauma, spinal cord injury, and performance' anxiety. In a study of the causes of ED in a group of Singaporean men, 72.5% were found to have an organic origin (mostly diabetes mellitus or vascular disease), while 27.5% had a psychogenic origin. 4 Available therapies for ED include psychosexual counselling (for those with a signi®cant psychogenic component), intracavernosal injections or transurethral delivery of alprostadil, vacuum-constriction devices, penile prostheses implantation, and arterial or venous surgery. 5 ± 7 A number of orally administered drugs have also been evaluated, including yohimbine, 8, 9 trazodone (and combinations of these agents), 10, 11 and phentolamine, 12 but their effectiveness has either not been well established or only demonstrated in a small number of patients or certain subsets of ED.
Recent clinical studies have shown sildena®l, an orally active inhibitor of cyclic guanosine monophosphate (cGMP)-speci®c phosphodiesterase type 5 13 to be effective in improving ED of various aetiologies. 14 ± 19 In addition, its effectiveness has also been demonstrated in various subsets of ED patients, including those with diabetes mellitus, 20 spinal cord injury, 21 antidepressant-induced dysfunction, 22 and following nerve-sparing radical prostatectomy. 23 These studies were mainly conducted in men living in western countries and as yet, the ef®cacy of sildena®l in Asian populations has not been widely evaluated. We therefore investigated the ef®cacy and safety of sildena®l in Asian men in Taiwan. The ASSESS-3 (Asian Sildena®l Ef®cacy and Safety Study-3) trial was a randomised, doubleblind, placebo-controlled,¯exible-dose study carried out at six different medical centres in Taiwan.
Materials and methods

Study population
The ASSESS-3 study was conducted during the period of September 1997 to March 1998 in 237 Taiwanese men aged 26 ± 80 y who had a welldocumented history (b6 months) of ED (NIH de®nition 1 ) of organic, psychogenic or mixed aetiology. The patients were required to be in a stable heterosexual relationship for at least the previous 6 months, and not to have any of the following: ED caused by genital anatomical abnormalities or spinal cord injury; other coexisting sexual disorders (eg hypoactive sexual desire); raised serum prolactin levels (b36upper limit of normal, ULN) or a low testosterone level (b20% below the lower limit of the normal range at 0900 ± 1100 h); a major psychiatric disorder or a history of alcohol or substance abuse; major haematological, renal or hepatic diseases; diabetes mellitus that is poorly controlled or associated with untreated proliferative retinopathy; a history of stroke or myocardial infarction within the previous 6 months; hypotension or any other signi®cant cardiovascular disease; or a history of retinitis pigmentosa. Patients were also excluded if they were receiving drugs known to be causally associated with ED, androgen therapy, trazodone, nitrates or nitric oxide donor compounds (in any form), and if they were using vacuum constricting devices or any other treatments for ED. Patients signed the informed consent to participate in the study, which was conducted in accordance with ethical committee regulations at each site.
Initially, the patients underwent a 4-week run-in period during which baseline data on their sexual activities were collected, a full medicaladrug history, physical examination, 12-lead ECG and standard laboratory safety tests were performed, and sitting blood pressure and heart rate were measured. The patients were also instructed in the use of event logs to record information on their erections, the sexual activity that took place, and medication details (number of tablets and when taken). As well as the initial screening visit, they were required to undergo a further ®ve clinic visits Ð at the start of treatment (week 0) and thereafter at weeks 2, 4, 8 and 12.
Study medication
Following the run-in period, eligible patients were randomised to receive either sildena®l (Viagra TM ) or a matching placebo in a double-blind manner for a period of 12 weeks. For the ®rst 2 weeks of the study, patients were instructed to take a 50 mg sildena®l tablet (or a matching placebo) as required 1 h prior to anticipated sexual activity and not more than once daily. At subsequent visits and at the discretion of the investigator, either an increase to 100 mg (if the response was not adequate) or a decrease to 25 mg (if higher doses were not well tolerated) was allowed.
Assessment of ef®cacy
The 15-question International Index of Erectile Function (IIEF) 24 was used to assess clinical ef®cacy. Patients completed this validated, multidimensional, self-administered questionnaire at the end of the run-in period and at the scheduled end of treatment (week 12) or at the time of discontinuation. In addition, ef®cacy was also assessed via patients' event logs of sexual activity and medication taken, which were reviewed at each visit, and via a global ef®cacy assessment of erections at the end of treatment or discontinuation. The investigators also assessed patients at each visit to determine whether the dose taken was optimal and whether they should continue in the trial. The primary ef®cacy variables were the responses to questions 3 and 4 of the IIEF questionnaire which assess the patients' ability to penetrate their partners during sexual intercourse and to maintain the erection after penetration, respectively. The secondary ef®cacy variables were: (1) the responses to the ®ve separate domains of sexual function assessed by the IIEF questionnaire, ie erectile function (questions 1 ± 5 and 15), intercourse satisfaction (questions 6 ± 8), orgasmic function (questions 9 and 10), sexual desire (questions 11 and 12), and overall satisfaction (questions 13 and 14); 24 (2) event log responses regarding the success of attempts at sexual intercourse; and (3) a global ef®cacy assessment in response to the question:`Has the treatment you have been taking over the past 4 weeks improved your erections?'
Assessment of safety
Patients were assessed for adverse events at each visit and all observed or reported events were recorded regardless of a suspected causal relationship to the study medication. Sitting blood pressure, heart rate and details of concomitant medications were also recorded at each visit, and a 12-lead ECG and standard laboratory tests of haematological and blood chemistry parameters were repeated at the end of treatment visit (week 12).
Statistical analyses
The treatment groups were checked for similarity with respect to demographic and event log variables using descriptive statistics. Primary ef®cacy variables were analysed for both the intent-to-treat population (patients who took at least one dose of the study medication and had at least one postrandomisation evaluation) and the evaluable population (patients who either completed the study, or did not complete it but had ef®cacy data available in de®ned windows and did not violate the protocol in any fundamental way). The secondary ef®cacy variables were analysed for the intent-to-treat population only. Each of the two primary ef®cacy variables was analysed separately using univariate analysis of covariance (ANCOVA). Responses to the ®ve domains of the IIEF sexual function questionnaire were also analysed using ANCOVA, as were the percentages of successful intercourse attempts derived from patients' event logs. Responses to the global ef®cacy assessment question were analysed using logistic regression. In all ANCOVA analyses, the model included terms for treatment, centre, baseline value of the ef®cacy variables, and twofactor interactions between treatment group and other model terms. Covariates modelled in all analyses included the duration of the disease, patient age, history of smoking, and disease aetiology. All tests of hypotheses were performed at the 5% signi®cance level using two-sided tests of signi®cance.
Results
Of the 237 patients who entered the trial, one did not take any study medication and was not included in the analyses. Baseline characteristics of the 236 patients who were randomised and took the study medication are shown in Table 1 . The mean ages and body weights of the two groups were similar, as was the mean duration of ED (approximately 4 y) and the distribution of the etiolgies of ED (ie organic, psychogenic or mixed). Among other diseases present, benign prostatic hyperplasia was the most common disorder (40 sildena®l group, 44 placebo) Ef®cacy and safety of oral sildena®l in Taiwan K-K Chen et al while antihypertensive drugs, principally a-adrenoceptor blockers and calcium channel blockers, were the most common concomitant medications (30 sildena®l group, 43 placebo). Twelve patients (eight receiving sildena®l, four receiving placebo) deviated from the protocol and were excluded from the intent-to-treat population, which therefore comprised of 224 patients (111 sildena®l, 113 placebo). In addition, one patient in each group had their medication discontinued due to adverse effects and one in each group due to lack of ef®cacy. Thus, 220 patients completed the trial, 109 of whom received sildena®l and 111 placebo. The evaluable patient population comprised 189 patients (92 sildena®l, 97 placebo), 47 being excluded mostly due to violation of an inclusion criterion (ED not b6 months duration).
The mean duration of treatment was 84 days in the sildena®l group and 83 days in the placebo group and the median number of doses taken was 35 and 41, respectively. The initial 50 mg dose (sildena®l or matching placebo) was increased in most patients during the trial and at the week 12 endpoint, 79 (72.5%) of the sildena®l group were taking the highest dose (100 mg), 29 (26.6%) the medium dose (50 mg), and 1 (0.9%) the lowest dose (25 mg). In the placebo group, the`high',`medium' and`low' doses were taken by 106 (95.5%), four (3.6%) and one (0.9%) patients, respectively ( Figure  1 ). Four patients receiving sildena®l and one receiving placebo had dose reductions due to adverse events, and a further four receiving sildena®l and two receiving placebo had temporary withdrawals due to adverse events.
Primary ef®cacy variables
Mean scores for IIEF questions 3 and 4 at baseline and at the end of treatment for the intent-to-treat populations of the sildena®l and placebo groups are shown in Table 2 . These two questions assess the frequency with which penetration was achieved during attempts at sexual intercourse and the frequency with which erections were able to be maintained after penetration, both questions having maximum scores of 5 (almost always or always) and minimum scores of 0 (did not attempt intercourse). The mean scores obtained in the two groups expressed as percentages of the maximum score for Figure 1 Percentages of patients taking each dose of sildena®l or placebo at baseline (week 0) and at weeks 2, 4, 8, and 12. All patients took a 50 mg dose (sildena®l or matching placebo) during the ®rst 2 weeks, after which their doses were either increased up to 100 mg if the response was insuf®cient, or decreased to 25 mg if higher doses were not well tolerated. 24 Ef®cacy and safety of oral sildena®l in Taiwan K-K Chen et al each question are shown in Figure 2 . For both ef®cacy variables, sildena®l was statistically signi®-cantly more effective than placebo (P`0.0001). Similar results were obtained in the evaluable population analysis (data not shown).
Secondary ef®cacy variables
The mean scores at baseline and at the end of treatment for the ®ve IIEF domains of sexual functioning (ie erectile function, intercourse satisfaction, orgasmic function, sexual desire and overall satisfaction) for the intent-to-treat populations of the two groups are shown in Table 2 , and the scores expressed as percentages of the maximum scores in Figure 3 . For all ®ve domains, sildena®l was statistically signi®cantly more effective than placebo (P`0.0001), although the number of attempts at sexual intercourse (IIEF question 6) was not signi®cantly different between the two groups (P 0.1155). In all cases, sildena®l was signi®cantly more effective than placebo in improving the sexual function domain (P`0.0001), although sexual desire was improved to a much lesser extent than the other domains. Data from the patients' event logs showed that the mean percentage of successful attempts at sexual intercourse was signi®cantly greater with sildena®l than with placebo (62% vs 30%, respectively; P`0.0001) ( Table 2 and Figure 4) . Similarly, responses to the global assessment question regarding erections at week 12 also elicited a statistically signi®cantly greater treatment effect with sildena®l than placebo (P`0.0001) (Figure 4 ).
Adverse events
All 236 patients who were randomised to treatment were included in the adverse event analysis, but laboratory test data were only available for 199 patients (101 receiving sildena®l and 98 placebo). Adverse events recorded during the trial, regardless of causality, are shown in Table 3 . Adverse events considered by the investigators to be treatmentrelated occurred in 52 patients (43.7%) receiving 13 and 14) . For all domains, scores were available for 110 patients receiving sildena®l and for 111 receiving placebo, except for the erectile function and overall satisfaction domains for which scores in the placebo group were available for 110 and 109 patients, respectively. *P`0.0001 vs placebo. Figure 4 Percentages of attempts at intercourse rated as successful (from data recorded in patients' event logs) and percentages of patients rating their erections as improved (as assessed via the global ef®cacy question) following administration of sildena®l or placebo for 12 weeks. *P`0.0001 vs placebo.
Ef®cacy and safety of oral sildena®l in Taiwan K-K Chen et al sildena®l and 22 (18.8%) receiving placebo. In the sildena®l group, the most commonly encountered adverse event was facial¯ushing, which was considered treatment-related in 30 (25.2%) patients, followed by dizziness (eight patients; 6.7%), headache (seven patients; 5.9%), and abdominal pain and palpitation (each in four patients; 3.4%). Most adverse events with sildena®l were mild in nature, and only one patient had a severe event (epigastralgia) that was considered treatment-related. This patient completed the study after having his sildena®l dose reduced. Only one patient receiving sildena®l required treatment to be discontinued due to a treatment-related adverse event Ð a moderate skin rash. Visual abnormalities were noted in only two patients (1.7%) ( Table 3) .
Serious adverse events occurred in four patients in the sildena®l group and four in the placebo group but none was considered treatment-related.
Laboratory results
Among the 199 patients for whom laboratory test results were available, two of 101 (2%) receiving sildena®l showed a clinically signi®cant laboratory abnormality as compared with six of 98 (6%) receiving placebo. The two patients receiving sildena®l both had raised serum potassium levels (b1.16ULN), while three receiving placebo also had raised serum potassium levels, one had a raised blood urea nitrogen level, one raised eosinophils, and one raised neutrophils. However, no patients were discontinued from the trial due to laboratory test abnormalities.
Discussion
Because of cultural beliefs, misinformation and the numerous myths that surround the condition, many Asian men with ED do not seek treatment for their condition for fear of personal embarrassment. Moreover, inexperience on the part of doctors who are consulted about it or, in some cases, reluctance to deal with the problem has led to disappointment for the sufferer and perpetuated the myth that there are no effective treatments for ED. This situation highlights the need for more open discussion and better education about ED and its origins, and for an effective therapy that is both simple and safe to use and does not interfere with the spontaneity of the sexual relationship.
In view of the reported ef®cacy of sildena®l in improving the sexual functioning of western men with ED of various aetiologies, 14 ± 23 its effectiveness and safety in our Asian population is of considerable interest and underlines the expanding role of Adverse events recorded regardless of a suspected relationship to the study medication. c Adverse events judged by the investigator to be treatment-related.
Ef®cacy and safety of oral sildena®l in Taiwan K-K Chen et al the drug in the management of ED. The bene®cial effect of sildena®l is related to enhancement of the normal erectile mechanism in response to erotic visual or genital stimuli. This process normally begins with the release of nitric oxide (NO) from nonadrenergic-noncholinergic nerves and endothelial cells of the corpus cavernosum which then activates guanylate cyclase, resulting in an increased synthesis of cGMP and hence a reduction in intracellular calcium and smooth muscle relaxation. 5, 25 Relaxation of smooth muscle in the corpus cavernosum and penile arteries results in an increased blood¯ow into the lacunar spaces of the corpus cavernosum and compression of the draining venules, leading to erection. 5 By inhibiting cGMPspeci®c phosphodiesterase type 5, which is the predominant form of the enzyme in the corpus cavernosum, sildena®l reduces the hydrolytic breakdown of cGMP and thus restores the normal erectile response to erotic stimuli. 13 This study in Taiwanese men has shown that ā exible dose regimen of sildena®l ranging from 25 to 100 mg taken 1 h prior to anticipated sexual activity is effective in improving ED of organic, psychogenic and mixed origins, as evaluated by the patients' own assessments in their own environments. The assessment methods used were the IIEF questionnaire, patient-compiled event logs of sexual activity, and a global ef®cacy question regarding erections. The IIEF questionnaire provides a broad measure of sexual functioning across ®ve domains and has adequate sensitivity for detecting treatment-related changes in erectile function, although it does have some limitations, eg the sole focus on sexual functioning and limited assessments of nonerectile components of the sexual response and the partner relationship. Despite this, the IIEF questionnaire has been widely used in studies evaluating the ef®cacy of therapies for ED and its adaptation to various Asian languages, including Mandarin and Cantonese Chinese and English dialects for use in Southeast Asian countries has not been found to be associated with cross-cultural problems of comprehension. 26 Both the primary and secondary ef®cacy variables used in this study showed signi®cantly greater treatment effects for sildena®l in comparison with placebo (P`0.0001). The only IIEF parameter that did not show a signi®cant difference between the two groups was the number of attempts at sexual intercourse (ie the responses to question 6:`How many times have you attempted sexual intercourse over the past 4 weeks?'), but data from the patients' event logs showed that the mean proportion of successful attempts at intercourse was more than doubled by sildena®l in comparison with placebo (62% of attempts vs 30%; P`0.0001).
Our results in Taiwanese men are similar to those reported in western populations, the improvements in the ability to achieve and maintain erections suf®cient for penetration andaor for the ®ve IIEF domains being comparable to those achieved in double-blind, placebo-controlled studies conducted in the US and UK. 14 ± 17 We employed a¯exible dose schedule of sildena®l, allowing for increases up to 100 mg for lack of ef®cacy or reductions to 25 mg for lack of tolerance. At the end of the 12-week study period, 72.5% of patients receiving sildena®l were found to be taking a 100 mg dose, while 26.6% were taking a 50 mg dose and 0.9% a 25 mg dose ( Figure  4 ). This ®nding is very similar to that reported by Goldstein et al, 14 who noted that 74% of patients in the¯exible-dose arm of their study were taking a 100 mg dose, while 23% were taking a 50 mg dose and 2% were taking a 25 mg dose after 12 weeks of therapy.
In our study, a statistically signi®cant increase in sexual desire was noted in patients on sildena®l compared to those on placebo. These results are different from that obtained in western populations. Although sexual desire was increased in our Taiwanese patients taking sildena®l, we believe it may be secondary to restored erectile function.
As regards safety, again, we have con®rmed the ®ndings of studies in western populations in demonstrating that sildena®l is well-tolerated in Taiwanese men, with no serious adverse events related to its use and no instances of priapism. The most common adverse events experienced by our patients were facial¯ushing (25.2%), dizziness (6.7%) and headache (5.9%), which re¯ect the pharmacological activity of the drug. In most cases, the adverse events were mild in nature and only one patient experienced a severe event (epigastralgia) which resolved after reducing the sildena®l dose. Adverse events led to a reduction in the dose of sildena®l in four patients and a temporary withdrawal of the drug in another four. However, there were no withdrawals due to laboratory abnormalities.
The absence of serious safety concerns in our patients con®rms the ®ndings of a clinical safety overview of 28 phase II or III studies with sildena®l conducted in western populations. 27 In this analysis, occurrence rates of myocardial infarction or other serious cardiovascular events were not increased in either the short-or long-term studies reviewed. Signi®cant changes in blood pressure, heart rate or ECG parameters were not observed either in this overview analysis of western studies 27 or in our study of men in Taiwan. Although 25% of our patients were receiving antihypertensive drugs (principally a-adrenoceptor blockers or calcium channel blockers) and 33% of patients in the placebo-controlled studies included in the overview analysis 27 were receiving antihypertensive treatment, the tolerability of sildena®l in these men was no different to that in patients not receiving antihypertensive drugs. However, in other studies, co-administration of sildena®l with nitrate drugs Ef®cacy and safety of oral sildena®l in Taiwan K-K Chen et al has been reported to result in clinically signi®cant decreases in blood pressure, and the use of sildena®l is clearly contraindicated in patients receiving organic nitrates in any form. A recent ACCaAHA consensus document in the US has also advised caution, depending on an individual clinical assessment, in: (1) patients with active coronary ischaemia not taking nitrates (eg those with a positive exercise test for ischaemia); (2) patients with congestive heart failure and borderline low blood pressure or borderline low volume status; (3) patients receiving complicated, multidrug antihypertensive regimens; and (4) patients receiving other drugs that may prolong the serum half-life of sildena®l (eg agents that are metabolised by or inhibit cytochrome P450 3A4 such as erythromycin or cimetidine). 28 
Conclusions
The results of this randomised, double-blind, placebo-controlled,¯exible-dose study conducted at six medical centres in Taiwan have indicated that sildena®l is effective in improving the sexual function of Taiwanese men with ED of organic, psychogenic and mixed etiologies. Both the primary and secondary ef®cacy variables evaluated showed statistically signi®cant treatment effects for sildena®l in comparison with placebo. This included the frequency of penetration and maintenance of an erection following penetration, the ®ve separate IIEF domains of sexual functioning, the percentage of successful attempts at intercourse, and global improvements in erections. Sildena®l was also well tolerated, and most adverse events were mild in nature. The most commonly encountered adverse events were facial¯ushing, dizziness and headache. The low rate of discontinuations due to adverse events suggest that sildena®l is likely to be wellaccepted by the patients presenting with ED.
